- Home
- JEF vs ROIV Comparison
JEF vs ROIV Comparison
Compare JEF & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JEF
- ROIV
- Stock Information
- Founded
- JEF 1968
- ROIV 2014
- Country
- JEF United States
- ROIV United Kingdom
- Employees
- JEF N/A
- ROIV N/A
- Industry
- JEF Investment Bankers/Brokers/Service
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- JEF Finance
- ROIV Health Care
- Exchange
- JEF Nasdaq
- ROIV Nasdaq
- Market Cap
- JEF 10.5B
- ROIV 8.6B
- IPO Year
- JEF N/A
- ROIV N/A
- Fundamental
- Price
- JEF $56.91
- ROIV $18.28
- Analyst Decision
- JEF Buy
- ROIV Strong Buy
- Analyst Count
- JEF 4
- ROIV 8
- Target Price
- JEF $71.00
- ROIV $19.94
- AVG Volume (30 Days)
- JEF 4.0M
- ROIV 7.7M
- Earning Date
- JEF 09-29-2025
- ROIV 11-11-2025
- Dividend Yield
- JEF 2.82%
- ROIV N/A
- EPS Growth
- JEF 25.06
- ROIV N/A
- EPS
- JEF 2.92
- ROIV N/A
- Revenue
- JEF $7,231,501,000.00
- ROIV $23,233,000.00
- Revenue This Year
- JEF $5.71
- ROIV N/A
- Revenue Next Year
- JEF $9.93
- ROIV $320.50
- P/E Ratio
- JEF $19.62
- ROIV N/A
- Revenue Growth
- JEF 15.68
- ROIV N/A
- 52 Week Low
- JEF $39.28
- ROIV $8.73
- 52 Week High
- JEF $82.68
- ROIV $18.42
- Technical
- Relative Strength Index (RSI)
- JEF 48.04
- ROIV 87.01
- Support Level
- JEF $48.51
- ROIV $16.89
- Resistance Level
- JEF $55.78
- ROIV $18.42
- Average True Range (ATR)
- JEF 2.50
- ROIV 0.52
- MACD
- JEF 0.23
- ROIV 0.08
- Stochastic Oscillator
- JEF 62.50
- ROIV 95.44
About JEF Jefferies Financial Group Inc.
Jefferies is a full-service investment banking and capital markets firm that was founded in 1962. After nearly 30 years of focusing on institutional trading services, it entered the investment banking industry in the early 1990s, which ultimately grew into the core business. In 2013, Jefferies merged with Leucadia, a manufacturing-focused holding company. Since merging, Jefferies became the bedrock of the business as the bulk of the legacy portfolio was sold off and the parent company was renamed to match the subsidiary. Within the investment banking landscape, Jefferies predominately serves the North American middle market and has captured considerable market share over the past decade.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.